2026 Top Innovations Winners Highlight Breakthrough Platforms in Single‑Cell Proteomics, Tumor Infiltration Assessment, and Drug Development Risk Prediction

By pioneering cutting‑edge technologies, startups are expanding the frontiers of life sciences. The 2026 Top Innovations winners in the Emerging Startup Technologies category have introduced platforms that reveal protein organization at the single‑cell level, predict immune‑cell tumor infiltration, and forecast drug‑development success. Below is a closer look at the three recognized technologies.

Pixelgen Proxiome Kit v2 Enables High‑Resolution Mapping of Single‑Cell Protein Interaction Networks

Understanding the functional states of individual cells requires looking beyond simple protein abundance to the clustering and interactions of proteins – the interactome. Researchers need scalable, high‑dimensional tools that can map complex surface‑protein architecture at single‑cell resolution without demanding costly, specialized equipment.

The Pixelgen Proxiome Kit v2, Immuno 155 v2 provides a unique capability to map the dynamic protein interactome of single cells, an understudied dimension in translational research. Launched in June 2026, the kit is a sample‑preparation system that delivers comprehensive analysis of the surface protein interactome of human immune cells at nanoscale resolution. It employs a DNA‑based proximity network assay that generates a three‑dimensional map of tens of thousands of molecular nodes per cell across a validated 155‑plex immune panel. Designed for accessibility, the high‑throughput workflow runs on standard molecular‑biology laboratories using existing next‑generation sequencing platforms, making it suitable for discovery‑scale and clinical‑scale studies. The kit also works with custom conjugation kits and antibodies targeting chimeric antigen receptors (CAR), allowing inclusion of proprietary or CAR‑T‑specific targets.

“It is giving us a glimpse of cellular physiology at a resolution that we’ve never seen before, enabling us to discover how cell surface proteins cooperate both in normal physiological processes and how it goes wrong in diseases like autoimmune diseases and cancer,” said Aaron Viny, a physician‑scientist at Columbia University Irving Medical Center, who uses the kit in his blood‑cancer research.

Viny compares standard single‑cell tools like flow cytometry to a city census, which can reveal how many schools, hospitals, or fire stations exist but cannot show whether those buildings are arranged sensibly across the city. With the Pixelgen Proxiome Kit v2, “we can see a city as through the lens of a city planner,” he explained. This spatial view allows his team to explore how abnormal cell‑surface protein organization drives disease and could help predict treatment response.

Adhesion Chromatography Platform by Infiltrate Bio Predicts Tumor Infiltration Potential of CAR‑T Cells

Engineering a patient’s immune cells to attack cancer has transformed blood‑cancer therapy, yet extending this approach to solid tumors remains challenging because engineered cells must first infiltrate the tumor mass. Traditional methods assess surface markers to infer trafficking, but animal studies are resource‑intensive and in‑vitro assays often lack the throughput or the dynamic flow conditions of real blood vessels. Infiltrate Bio’s Adhesion Chromatography (A‑Chip) addresses these gaps.

The A‑Chip is an acellular, biomimetic microfluidic platform (research‑use‑only) that separates cells based on how they adhere to the human vascular adhesion molecules that line tumor blood vessels. Its U‑shaped channel recreates physiological blood flow, while functionalized surfaces present the same adhesion molecules found in solid‑tumor endothelium. As cells travel through the device they roll, slow, and adhere in the same steps that a T cell uses to exit the circulation and enter tissue, generating quantitative adhesion phenotypes that predict tumor infiltration. According to Jon Chen, CEO and co‑founder of Infiltrate Bio, the platform’s “reach extends well beyond cancer into immune therapies for autoimmune, inflammatory, and neurological diseases, as well as age‑related immune changes.”

Sarwish Rafiq, a cancer biologist at Emory University School of Medicine, uses the A‑Chip to study solid‑tumor CAR‑T cells, predict infiltration, and correlate this with survival in preclinical models. “Many of the standard in‑vitro assays used to characterize CAR‑T cells are not accurate indicators of how these cells will perform in vivo,” Rafiq wrote. “A‑Chip…has streamlined our CAR‑T cell development process.”

Derisq by GATC Health Provides Early‑Stage Risk Scoring for Drug Candidates

Drug developers often must make pivotal decisions before sufficient data are available to gauge a candidate’s likelihood of success. GATC Health’s Derisq is an AI‑driven risk and prioritization report that simulates human biology to evaluate efficacy, safety, toxicity, off‑target effects, pharmacokinetics, endpoints, and patient selection, then integrates these factors into a probability‑of‑success assessment. The system, launched on October 7 2025 at Fierce Biotech Week in Boston, is already being used commercially for pipeline evaluation and clinical‑trial risk analysis.

Derisq produces a decision‑ready, asset‑specific benchmark that is comparable to approved and failed drugs. It helps teams spot risks early, prioritize stronger candidates, address fixable problems, or halt weaker programs before large resource commitments. Jayson Uffens, GATC Health’s co‑founder and CTO, likens the approach to a credit score for drug assets, providing a common standard for risk assessment before real capital is committed. Clinical leaders such as David J. Mazzo of Lisata Therapeutics note that Derisq adds a predictive layer that addresses the gap of incomplete biological insight in early development decisions.

Source link